Adaptation Or Attenuation Of Cells Patents (Class 435/245)
-
Publication number: 20080199926Abstract: The invention provides a non-naturally occurring microorganism having one or more gene disruptions, the one or more gene disruptions occurring in genes encoding an enzyme obligatory coupling 3-hydroxypropionic acid production to growth of the microorganism when the gene disruption reduces an activity of the enzyme, whereby the one or more gene disruptions confers stable growth-coupled production of 3-hydroxypropionic acid onto the non-naturally occurring microorganism.Type: ApplicationFiled: January 22, 2008Publication date: August 21, 2008Inventors: Anthony P. Burgard, Stephen J. Van Dien
-
Publication number: 20080090283Abstract: Ethanol and furfural challenged strains of E. coli FBR5 exhibiting higher ethanol yield, productivity, and tolerance to both ethanol and furfural than FBR5 and methods for producing same.Type: ApplicationFiled: October 12, 2007Publication date: April 17, 2008Applicant: Rowan UniverstityInventors: Brian Gerald Lefebvre, Mariano Javier Savelski, Gregory B. Hecht
-
Patent number: 7354593Abstract: The present invention relates to a vaccine for coccidiosis in chickens prepared from three attenuated Eimeria species: E. acervulina, E. maxima and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.Type: GrantFiled: February 6, 2006Date of Patent: April 8, 2008Assignees: Merial Limited, University of Georgia Research Foundation, Inc.Inventors: Larry R. McDougald, Alberta Lorraine Fuller, Joyce Anita Pritchard
-
Publication number: 20080026999Abstract: The present invention relates to two-component lantibiotics isolated from Bacillus sp. Methods for producing said lantibiotics are provided, wherein dehydration and cyclization of the peptides is carried out by two substrate-specific modifying enzymes. Given the antimicrobial activity of the instant lantibiotics, methods for preventing or treating bacterial infections are also provided.Type: ApplicationFiled: June 26, 2007Publication date: January 31, 2008Inventor: Wilfred A. van der Donk
-
Patent number: 7319028Abstract: The present invention provides a process for efficiently producing sporangia of Bacillus popilliae containing spores and parasporal bodies having controlling effects on Scarabaeidae insects, and a control agent and controlling method for Scarabaeidae insects obtained by said production process. In a process for producing sporangia of Bacillus popilliae containing spores and parasporal bodies by culturing Bacillus popilliae in a medium containing an adsorbent, the medium contains 0.2-4.0% by weight of glutamic acid.Type: GrantFiled: December 9, 2003Date of Patent: January 15, 2008Assignees: Dainippon Ink and Chemicals, Inc., Chiba Prefectural GovernmentInventors: Gaku Ehara, Masaharu Kimura, Hideji Nishihashi, Tomoko Yokoyama, Makoto Hasegawa, Masao Tanaka, Azusa Fujiie, Shinichi Aoyagi
-
Publication number: 20070281904Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.Type: ApplicationFiled: January 24, 2007Publication date: December 6, 2007Inventors: Shenda Baker, William P. Wiesmann, Shannon Ryan
-
Patent number: 7294491Abstract: The present invention provides a method for producing L-glutamic acid by fermentation, by culturing in a liquid medium a microorganism that can metabolize a carbon source at a specific pH, and wherein said medium contains a carbon source and L-glutamic acid at a saturation concentration, and wherein said microorganism is able to cause accumulation of an amount of L-glutamic acid in a liquid medium having said pH, wherein said amount exceeds the amount of L-glutamic acid at said saturation concentration when the pH of the medium is controlled so that L-glutamic acid is precipitated, making L-lysine exist in the medium when L-glutaminc acid concentration is lower than the concentration at which natural crystallization of L-glutamic acid occurs, and precipitating the ?-form crystals of L-glutamic acid.Type: GrantFiled: November 3, 2005Date of Patent: November 13, 2007Assignee: Ajinomoto Co., Inc.Inventors: Hiroshi Ueda, Kunihiko Toumori
-
Patent number: 7235246Abstract: The present invention relates to the preparation of universal inactivated vaccines and their use in preparing compositions for the prophylaxis and therapy of dermatomycosis. Vaccines according to the present invention have the advantage of conferring immunity against all important causes of dermatomycosis in animals and are characterized by stable immunogenic properties, easy preparation, high content of microconidia and lack of side reactions in animals.Type: GrantFiled: April 21, 2004Date of Patent: June 26, 2007Assignee: Boehringer Ingelheim Vetmedica, GmbHInventors: Igor Polyakov, Ludmilla Ivanova
-
Patent number: 7192754Abstract: A material and a system are provided that efficiently inactivate a molting hormone by means of a protein having ecdysteroid 22-oxidase activity.Type: GrantFiled: February 23, 2001Date of Patent: March 20, 2007Assignee: National Institute of Agrobiological SciencesInventors: Manabu Kamimura, Makoto Kiuchi, Hitoshi Saito, Maroko Myohara
-
Patent number: 7138126Abstract: A method for modifying a wild strain of an entero-invasive Shigella to produce a modified strain of Shigella that can be used for making a vaccine against the wild strain of Shigella. The genome of the wild strain of Shigella is transformed so that it cannot substantially invade cells of a human host and cannot spread substantially within infected cells and from infected to uninfected cells of the host and cannot produce toxins which will kill substantial numbers of the host's infected, as well as uninfected, cells. A first gene of the wild strain of Shigella, coding for a protein necessary for the Shigella to invade cells of the host, and a second gene, coding for a protein necessary for the Shigella to spread within infected cells and between the infected and uninfected cells of the host, are mutagenized.Type: GrantFiled: April 1, 2004Date of Patent: November 21, 2006Assignee: Institut PasteurInventors: Philippe Sansonetti, Annick Fontaine
-
Patent number: 7119167Abstract: The present invention relates to a 2227-bp DNA fragment that confers antiphage activity. Two proteins encoded by this DNA sequence are responsible for the phage resistance phenotype. When introduced in Lactococcus lactis phage-sensitive strain, this DNA fragment aborts infection of phages of the 936 and P335 species.Type: GrantFiled: April 5, 2002Date of Patent: October 10, 2006Assignee: Université LavalInventors: Sylvain Moineau, Julie Bouchard, Éric Dion
-
Patent number: 7045336Abstract: We describe a bacterial delivery system for the delivery of DNA and antigens into cells. We constructed an attenuated bacterial vector which enters mammalian cells and ruptures delivering functional plasmid DNA and antigens into the cell cytoplasm. This Shigella vector was designed to deliver DNA to colonic surfaces, thus opening the possibility of oral and other mucosal DNA immunization and gene therapy strategies. The attenuated Shigella is also useful as a vaccine for reducing disease symptoms caused by Shigella.Type: GrantFiled: September 6, 1996Date of Patent: May 16, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Arthur A. Branstrom, Donata R. Sizemore, Jerald C. Sadoff
-
Patent number: 6998127Abstract: The present invention relates to a vaccine for coccidiosis in chickens prepared from four attenuated Eimeria species: E. acervulina, E. maxima, E. mitis and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.Type: GrantFiled: April 15, 2005Date of Patent: February 14, 2006Assignee: Merial LimitedInventors: Larry R. McDougald, Alberta L. Fuller
-
Patent number: 6984388Abstract: A safe and effective live vaccine against Flavobacterium columnare of fish was created through the induction of an adhesion deficient isolate of Flavobacterium columnare using a ?-lactam antibiotic (ampicillin). Single immersion exposure of fish stimulated acquired immunity against virulent F. columnare infection.Type: GrantFiled: February 6, 2004Date of Patent: January 10, 2006Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Joel A. Bader, Craig A. Shoemaker, Phillip H. Klesius
-
Patent number: 6939705Abstract: A bacterial cell having protection against conditions which are lethal to an unprotected bacterial cell wherein, the protected cell is obtained by subjecting a bacterial cell to treatment with a sublethal level of stress.Type: GrantFiled: June 9, 2000Date of Patent: September 6, 2005Assignee: Nestec S.A.Inventors: Gudrun Schmidt, Ralf Zink
-
Patent number: 6916478Abstract: The invention relates to novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, methods for preparing same, and their use in the prevention and treatment of infectious diseases.Type: GrantFiled: September 6, 2002Date of Patent: July 12, 2005Assignee: University of GuelphInventors: Jagath L. Kadurugamuwa, Terry J. Beveridge
-
Patent number: 6916646Abstract: Methods are provided for preparing improved fermentation strains of the family Enterobacteriaceae which comprise the steps of eliminating the cryptic plasmid from the progenitor strain thereby creating the improved strain. Methods for reducing the mobilization properties of resident plasmids in an Enterobacteriaceae strain containing a cryptic plasmid are also provided. The present invention provides the nucleic acid sequence of pS, a cryptic plasmid found in Pantoea which can be used to identify the cryptic plasmid in strains of Enterobacteriaceae.Type: GrantFiled: June 23, 1997Date of Patent: July 12, 2005Assignee: Genencor International, Inc.Inventors: Timothy Fowler, Stuart C. Causey
-
Patent number: 6908620Abstract: The present invention relates to a vaccine for coccidiosis in chickens prepared from four attenuated Eimeria species: E. acervulina, E. maxima, E. mitis and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.Type: GrantFiled: December 8, 2003Date of Patent: June 21, 2005Assignee: University of Georgia Research Foundation, Inc.Inventors: Larry R. McDougald, Alberta L. Fuller
-
Patent number: 6890542Abstract: The present invention relates to the use of a live mutant Leishmania in the preparation of a vaccine and to vaccine formulations for use in immunizing mammals, such as dogs and/or humans. The mutant Leishmania comprises at least one defective cysteine proteinase gene.Type: GrantFiled: April 24, 2003Date of Patent: May 10, 2005Assignee: University Court of the University of GlasgowInventors: Jeremy Charles Mottram, Graham Herbert Coombs
-
Patent number: 6787360Abstract: The present invention provides a isolated bacteriophage useful as a tool for studying biological, biochemical, physiological and genetic properties of actinomycetes and other organisms which comprises a novel strain of Saccharomonospora having certain specified characteristics. The invention also relates to a process for the isolation of the said bacteriophage and/or DNA phage and to a novel universal growth medium which is particularly useful in the said process. Another embodiment of the process relates to a clonong vector which comprises a plasmid or bacteriophage comprising the phage DNA of the invention.Type: GrantFiled: May 13, 2002Date of Patent: September 7, 2004Assignee: Council of Scientific and Industrial ResearchInventors: Pushpa Agrawal, Vishal Soni
-
Patent number: 6770275Abstract: The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.Type: GrantFiled: May 30, 1997Date of Patent: August 3, 2004Assignee: Akzo Nobel N.V.Inventors: Ruud Philip Antoon Maria Segers, Johannes Franciscus Van Den Bosch, Joachim Frey
-
Patent number: 6759230Abstract: A novel microorganism producing a nontoxic, non-antigenic exopolysaccharide is taught. The exopolysaccharide has neutral sugars migrating at the same rate as mannose, fucose, fructose and galactose, acidic sugars migrating at the same rate as fucose and amine sugars migrating at the same rate as glucose and fucose, and wherein the ratio of galactose:fucose:glucose:mannose is about 1:2:3:6. The microbe and the exopolysaccharide have uses as a biofilm in geologic applications and have several consumer uses as food and drug polymers and use as a plasma extender.Type: GrantFiled: October 25, 2000Date of Patent: July 6, 2004Assignee: The Board of Regents, The University of TexasInventors: Lee A. Bulla, Jr., Mehmet Candas
-
Patent number: 6682914Abstract: Newly-isolated and purified metabolites which are effective in regulating the development of at least one filamentous fungal microorganism species are disclosed. These compounds, which are referred to as conidiogenol and conidiogenone, may be used to induce conidiation in and/or to inhibit the growth of populations of such fungal species. The compounds are preferably produced by culture of the fungal species Penicillium cyclopium, and may be subsequently recovered from the culture medium and purified. Methods of using and methods of producing these compounds are also disclosed.Type: GrantFiled: October 31, 2001Date of Patent: January 27, 2004Assignee: Universidad del Pais Vasco/Euskal Herriko UnibersitateaInventors: Unai Ugalde, Tomas Roncal, Olov Sterner
-
Patent number: 6653135Abstract: An assay to determine the specific expression and suppression of proteins in response to a stressor is disclosed. An organism exposed to a stressor, including disease caused by exposure to, e.g., a parasite, or a substance suspected of causing an adverse effect, is assayed to determine a first set of proteins expressed and a second set of proteins suppressed in response to the stressor. The amount of each protein expressed and the amount of each protein suppressed can be statistically analyzed to determine which proteins are most useful in diagnosing the stressor. A protein profile for a first stressor can be compared to protein profiles for a second stressor, a third stressor, etc. A distinct protein expression signature (PES) for the first stressor can be identified by determining subsets fo proteins expressed and/or suppressed only in response to the first stressor.Type: GrantFiled: September 13, 2000Date of Patent: November 25, 2003Assignee: University of MarylandInventor: Brian P. Bradley
-
Patent number: 6593087Abstract: This invention describes novel purified and isolated nucleic acid molecules or the fragments thereof, extracted from nematode or arthropod pests or recombinant, which encode P-glycoprotein homologs and regulate resistance to the macrocyclic lactone compounds. The invention further relates to the new P-glycoprotein homolog expression product of these nucleic acids. Also described herein are methods for detecting the gene encoding for resistance to the macrocyclic lactone compounds in nematode or arthropod pests which comprise comparing the nucleic acids extracted from a pest specimen to the nucleic acids encoding for resistance and the nucleic acids encoding for susceptibility to the macrocyclic lactone compounds.Type: GrantFiled: December 27, 2000Date of Patent: July 15, 2003Assignee: McGill UniversityInventors: Roger K. Prichard, Ming Xu, Ana Paula Ribeiro, William J. Blackhall, Robin N. Beech, Marcelo Molento, Hao Yuan Liu
-
Patent number: 6589771Abstract: A method for arousing dormant bacteria. The method comprises inducing diffusion of intracellular solutes from dormant bacteria and then allowing an adjustment period for a length of time sufficient to initiate arousal. The decrease in intracellular osmolality or pH can be induced by methods such as extraction, dilution, or dialysis. The method has been standardized using Dulbecco's phosphate buffered saline as the solution. The aroused bacteria can then be selected or recovered by growing them on media for a period of time. If the adjustment period is prolonged, many bacteria can become hypermutative.Type: GrantFiled: October 28, 1999Date of Patent: July 8, 2003Assignee: Immunom Technologies, Inc.Inventor: William E. Marshall
-
Patent number: 6534054Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.Type: GrantFiled: November 13, 2001Date of Patent: March 18, 2003Assignee: The Bio Balance CorporationInventors: Mark Olshenitsky, Genadi Buchman
-
Patent number: 6514494Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.Type: GrantFiled: November 13, 2001Date of Patent: February 4, 2003Assignee: The Bio Balance CorporationInventors: Mark Olshenitsky, Genadi Buchman
-
Publication number: 20020173031Abstract: The present invention relates to methods for modulating the resistance of cells to foreign compounds, i.e. drugs, antibiotics, etc by altering the ATP gradient across biological membranes. The altering of the ATP gradient across biological membranes is achieved through the manipulation of ecto-phosphatase activity and ABC transporter molecule activity which may be useful to confer herbicide resistance to plants, confer antibiotic resistance to bacteria, confer drug resistance to yeast cells, or to reduce resistance in cells to facilitate chemotherapeutic treatments, and to reduce resistance in bacteria and yeast. The present invention is also directed to the methods for identifying ecto-phosphatase inhibitors and uses thereof.Type: ApplicationFiled: January 14, 2002Publication date: November 21, 2002Applicant: The University of Texas SystemInventors: Collin E. Thomas, J. Brian Windsor, Stan J. Roux, Alan M. Lloyd, Laurence Hurley
-
Publication number: 20020127701Abstract: A method of disrupting biological material includes drying particulate material, mixing the material with a gas under pressure, releasing the pressure explosively and collecting the resultant product. The biological starting material is any particulate material and includes: cells with membranes, cells with rigid cell walls, non-cellular biological material, intra-cellular material, and unbounded homogenous material. Apparatus for batch, semi-continuous and continuous operation of the method is provided. Included is a chamber with at least one inlet valve and at least one outlet valve and collection means. The chamber is capable of withstanding at least 800 bar, preferably 30 bar pressure. The particle size of the starting material is in the range 0.1 to 2000 &mgr;m and of the resultant product, less than 2 &mgr;m.Type: ApplicationFiled: November 30, 1999Publication date: September 12, 2002Inventor: KELVIN WINSTON DUNCAN
-
Patent number: 6410265Abstract: This invention relates to the isolation of a novel putative efflux gene from Pseudomonas mendocina. The putative efflux gene is useful for probing an organism's efflux system to gain an understanding of the mechanisms of solvent tolerance. The invention further provides a Pseudomonas mendocina strain deficient in this gene. This strain is unable to grow in the presence of chloramphenicol and, compared to the wildtype strain, grows slowly in the presence of high concentrations of PHBA.Type: GrantFiled: October 30, 1998Date of Patent: June 25, 2002Assignee: E. I. du Pont de Nemours and CompanyInventor: Kevin Keqin Chen
-
Patent number: 6410021Abstract: A live vaccine of recombinant mutants of a member of the family Pasteurellaceae lacking a rib gene necessary for production of riboflavin as well as a method of vaccination therewith is described. The vaccine is effective against members of the family Pasteurellaceae.Type: GrantFiled: April 22, 1998Date of Patent: June 25, 2002Inventors: Troy E. Fuller, Martha H. Mulks, Bradley Thacker
-
Patent number: 6410012Abstract: This invention pertains in part to a method for delivering functional DNA or antigens. The desired DNA is introduced into attenuated bacteria able to enter cells. Once the bacteria is in the cell, antimicrobial agents are introduced such that they enter the mammalian cell and lyse the bacteria thereby allowing the delivery of carried functional DNA or antigens. The advantages of this method and its uses are described.Type: GrantFiled: March 27, 1998Date of Patent: June 25, 2002Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Donata R. Sizemore, Jerald C. Sadoff, Jason C. Grove
-
Patent number: 6376228Abstract: A method for vaccinating poultry to prevent salmonellosis and other microbial-related health problems in humans is described. The method involves isolation of a poultry heterophil-adapted strain of a microorganism that may be used in a vaccine. A vaccine comprising a preparation of the poultry heterophil-adapted strain is administered to poultry to reduce the transmission of microorganisms causing salmonellosis and other illnesses.Type: GrantFiled: May 23, 2000Date of Patent: April 23, 2002Assignee: Iowa State University Research Foundation, Inc.Inventor: Theodore T. Kramer
-
Patent number: 6376245Abstract: The invention provides a process for protecting whole eukaryotes or parts thereof from an invasive attack from an invasive agent which comprises, selecting a prokaryotic bacterium which is capable of forming an L-form association with a host eukaryote and introducing an L-form bacteria into said host, wherein the bacteria is also selected to be antagonistic to the invasive agent. This process allows the protection of plants and plant parts against invasive organisms with which they have not already had contact.Type: GrantFiled: June 14, 2000Date of Patent: April 23, 2002Assignee: Aberdeen UniversityInventor: Alan McEwan Paton
-
Publication number: 20020045587Abstract: The invention relates to the introduction of DNA or RNA sequences into a mammalian cell to achieve controlled expression of a polypeptide. It is therefore useful in gene therapy, vaccination, and any therapeutic situation in which a polypeptide should be administered to a host or cells of said host, as well as for the production of polypeptides by mammalian cells, e.g., in Culture or in transgenic animals.Type: ApplicationFiled: March 22, 2000Publication date: April 18, 2002Inventor: Werner Goebel
-
Patent number: 6350608Abstract: A process is provided for the biological digestion of animal carcasses. First, the carcass is cut into smaller pieces with equipment that masticates, grinds or comminutes in the presence of water to create a solid-liquid mixture. The next steps include treating the solid-liquid mixture with a special blend or combination of bacteria that have been specifically cultured to digest the carcass; the mixture is subsequently aerated to form a stabilized biomass. The stabilized biomass is aerated in an open basin to further digest and liquefy the carcass, water, bacteria mixture. From the open basin, the primarily liquid waste stream is passed to a clarifying tank where the suspended solids are precipitated as sludge, thus clarifying the liquid. Sludge is removed from the clarifying chamber and the clarified liquid is either discharged or recirculated for further use in this novel process.Type: GrantFiled: December 22, 1999Date of Patent: February 26, 2002Assignee: AJT & Associates, Inc.Inventors: Alfredo J. Teran, Richard G. Wood, W. Todd Willoughby
-
Patent number: 6323025Abstract: Compounds termed “vitaletheine modulators” which include beta-alanyl-taurine and carbobenzoxy beta-alanyl-taurine are synthesized and added to culture media for in vitro culture of cells such as mammalian or plant cells. The compounds support cell vitality, and provide increased cellular life span, increased cellular bioproductivity, improved cellular function, and adaption of resistant cells to culturing. The compounds further delay senescence, optimize growth and maturation, and increase population doublings.Type: GrantFiled: June 5, 1995Date of Patent: November 27, 2001Assignee: University of New MexicoInventors: Galen D. Knight, Terence J. Scallen
-
Patent number: 6312955Abstract: The present invention features gram-positive bacteria resistant to 5-fluorodeoxyuridine (FUdR). Such bacteria will preferably be commensal, and will not be resistant to antibiotics. Bacteria according to the present invention may also be transformed with DNA encoding an antigenic protein. Such transformed bacteria may be used to formulate a vaccine, in order to stimulate an immune response to the antigenic protein in a patient. The present invention further provides a method for isolating gram-positive bacteria resistant to FUdR.Type: GrantFiled: April 29, 1999Date of Patent: November 6, 2001Assignee: Siga PharmaceuticalsInventors: Dennis E. Hruby, Christine A. Franke
-
Patent number: 6309650Abstract: An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell is disclosed. A Japanese encephalitis vaccine comprising said attenuated virus is also disclosed.Type: GrantFiled: June 15, 2000Date of Patent: October 30, 2001Assignees: Cheil Jedang Corporation, The United States of America as represented by the Secretary of the ArmyInventors: Hyun Su Kim, Wang Don Yoo, Soo Ok Kim, Sung Hee Lee, Sang Bum Moon, Sun Pyo Hong, Yong Cheol Shin, Yong Ju Chung, Kenneth H. Eckels, Bruce Innis, Joseph R. Puniak, Leonard N. Binn, Ashok K. Srivastava, Doria R. Dubois
-
Patent number: 6294351Abstract: A method of biochemically transforming macromolecular compounds found in solid carbonaceous materials, such as coal is provided. The preparation of new microorganisms, metabolically weaned through challenge growth processes to biochemically transform solid carbonaceous materials at extreme temperatures, pressures, pH, salt and toxic metal concentrations is also disclosed.Type: GrantFiled: October 15, 1998Date of Patent: September 25, 2001Assignee: Brookhaven Science Associates, LLCInventors: Mow S. Lin, Eugene T. Premuzic
-
Patent number: 6287873Abstract: A microbial consortium, ATCC 202177, is enriched to remove target sulfur compounds from gases in the presence of ammonia, cyanide, carbon monoxide, and other toxic gases and mixtures thereof. The ATCC 202177 consortium is cultured in an anaerobic or aerobic nutrient medium until enough cells of ATCC 202177 are recovered to remove the target sulfur species at a pressure ranging from 1 to 80 atmospheres.Type: GrantFiled: March 3, 1999Date of Patent: September 11, 2001Assignee: Arctech Inc.Inventors: Kailish C. Srivastava, Seema Garg, Daman S. Walia
-
Publication number: 20010018204Abstract: Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.Type: ApplicationFiled: January 22, 2001Publication date: August 30, 2001Inventors: Adonia E. Papathanassiu, Shawn J. Green
-
Patent number: 6235517Abstract: This invention relates to the isolation of thermophilic phytase-producing microorganisms, method for producing phytase using such microorganisms, phytase obtained therefrom, and usage of the phytase to hydrolyze phytic acid or phytate. In particular, this invention relates to phytase-producing microorganisms, which belong to Streptomyces sp., Pseudonocardia sp. or Microbispora sp., and which produce phytase available for recovery in an efficient and practical manner.Type: GrantFiled: November 9, 1999Date of Patent: May 22, 2001Assignee: Food Industry Research & Development InstituteInventors: Jaw-Shiow Chu, Su-Fang Chung, Min Tseng, Chiou-Yen Wen, Wen-Shen Chu
-
Patent number: 6204003Abstract: The claimed invention is a method for determining whether a mammal is infected with Haemobartonella felis or for inducing an immune response against Haemobartonella felis using a polypeptide expressed by Mycoplasma. Preferably, the polypeptide is expressed by Mycoplasma gallisepticum. In a preferred embodiment the polypeptide is the pMGA protein expressed by the strain of Mycoplasma gallisepticum having ATCC deposit number 19610.Type: GrantFiled: September 18, 1998Date of Patent: March 20, 2001Assignee: Synbiotics CorporationInventors: J. Kevin Steele, David L. Telford, John A. Cutting
-
Patent number: 6180390Abstract: This invention relates to the isolation of thermophilic phytase-producing microorganisms, method for producing phytase using such microorganisms, phytase obtained therefrom, and usage of the phytase to hydrolyze phytic acid or phytate. In particular, this invention relates to phytase-producing microorganisms, which belong to Streptomyces sp., Pseudonocardia sp. or Microbispora sp., and which produce phytase available for recovery in an efficient and practical manner.Type: GrantFiled: November 9, 1999Date of Patent: January 30, 2001Assignee: Food Industry Research & Development InstituteInventors: Jaw-Shiow Chu, Su-Fang Chung, Min Tseng, Chiou-Yen Wen, Wen-Shen Chu
-
Patent number: 6136554Abstract: The present invention is directed to methods and media for the growth, enrichment, isolation, and presumptive identification of enteric pathogens such as E. coli 0157:H7 and Salmonella. In particular, the organisms commonly associated with gastrointestinal infections of humans and other animals are distinguished based on their growth, colonial morphology and color. The present invention is also directed to methods and media for the growth, enrichment, isolation and presumptive identification of enteric pathogens such as E. coli 0157:H7 and Salmonella isolated from food, water, dairy, and environmental samples.Type: GrantFiled: March 17, 1997Date of Patent: October 24, 2000Assignee: Biolog, Inc.Inventor: Barry Bochner
-
Patent number: 6132709Abstract: A method for treating cattle and sheep to prevent foot rot and/or liver necrosis comprising administering a Fusobacterium necrophorum bacterin which is a .beta.-propriolactone inactivated Fusobacterium necrophorum isolate to the animal being treated.Type: GrantFiled: January 24, 1992Date of Patent: October 17, 2000Assignee: Bayer CorporationInventor: John N. Berg
-
Patent number: 6120774Abstract: A method for vaccinating poultry to prevent salmonellosis and other microbial-related health problems in humans is described. The method involves isolation of a poultry heterophil-adapted strain of a microorganism that may be used in a vaccine. A vaccine comprising a preparation of the poultry heterophil-adapted strain is administered to poultry to reduce the transmission of microorganisms causing salmonellosis and other illnesses.Type: GrantFiled: February 14, 1997Date of Patent: September 19, 2000Assignee: Iowa State University Research Foundation, Inc.Inventor: Theodore T. Kramer
-
Patent number: RE39494Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Bordetella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.Type: GrantFiled: August 5, 2004Date of Patent: February 27, 2007Assignee: Intervet Inc.Inventors: Gerald R. Fitzgerald, C. Joseph Welter